Editor’s pick: Bioptimus

T1Covered by 1 source · first reported by Nature / Science / Nature Biotechnology at 19 Oct, 00:00 UTC

Nature Biotechnology, Published online: 19 October 2026; doi:10.1038/s41587-026-03345-4 Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. Bioptimus is developing multimodal and multiscale AI pathology models for biomarker and drug…

Sources

• T1Editor’s pick: BioptimusNature / Science / Nature Biotechnology19 Oct, 00:00